Skip to content

A trial of fructose-di-phosphate treatment in oleander poisoning

Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced cardiac toxicity: a randomised controlled double-blind study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71018309
Enrollment
240
Registered
2009-01-16
Start date
2009-02-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac toxicity from oleander self-poisoning Injury, Occupational Diseases, Poisoning Toxic effect of other noxious substances eaten as food

Interventions

Patients will be randomised to FDP (250 mg/kg loading dose over 20 minutes followed by 6 mg/kg/hr for 24 hours) or a placebo in a 1:1 ratio (i.e 120 patients will receive FDP and 120 patients will rec

Sponsors

South Asian Clinical Toxicology Research Collaboration (SACTRC) (Sri Lanka)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients (greater than 12 years of age, both sexes) with any of the following manifestations of oleander-induced cardiac toxicity: 1. Second degree heart block 2. Third degree heart block 3. Bradycardia with a heart rate of less than 40 beats/minute 4. Any rhythm with a systolic blood pressure below 80 mmHg

Exclusion criteria

Exclusion criteria: 1. Patients with documented ischaemic heart disease or valvular heart disease. These patients may still be eligible for open label compassionate use of FDP. 2. Patients presenting with cardiac arrest on admission. These patients will be eligible for open label compassionate use of FDP. 3. Age less than 12 years

Design outcomes

Primary

MeasureTime frame
Reversion to sustained sinus rhythm with a heart rate greater than 50/minute within 2 hours of completion of bolus.

Secondary

MeasureTime frame
1. Death 2. Reversal of hyperkalaemia on the 6, 12,18 and 24 hour samples 3. Maintenance of sinus rhythm on the Holter monitor (reflecting the efficacy of the infusion)

Countries

Sri Lanka

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026